Looking to publish in Liver Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginLiver Cancer publishes clinical and translational research on the causes, mechanisms, prevention, surveillance, diagnosis, and treatment of liver malignancy in humans and experimental models, including molecular targeted therapy, in the form of original and review articles.
Looking to publish in Liver Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Liver Cancer accepts the following article types. Click on an article type to view submission instructions.
Research Article
Review Article
Systematic Review
Brief Report
Case Report
Guidelines
Letter
Registered Report-Stage 1
Registered Report-Stage 2
Recent Publications
Spatiotemporal, Statistical, and Anatomical Considerations for Translating Multi-Omics Cholangiocarcinoma Subtypes into Immunotherapy Biomarkers
Shiyuan Li, Meng Xia
Quavonlimab Coformulated With Pembrolizumab Plus Lenvatinib for Advanced Hepatocellular Carcinoma: Nonrandomized Phase 2 KEYSTEP-004 Trial
Daneng Li, Lorenza Rimassa, Masafumi Ikeda, Mark Yarchoan, Baek-Yeol Ryoo, Thibaud Koessler, Ho Yeong Lim, Mariusz Kwiatkowski, Ting-Tsung Chang, Jee Hyun Kim, Andrea Casadei Gardini, Masatoshi Kudo, ZhengGang Ren, Maria Varela, Josep M Llovet, Razi Ghori, Ken Hatogai, Abby B Siegel, Ann-Lii Cheng
Dietary cholesterol promotes MASLD-related hepatocellular carcinoma through mitochondrial dysfunction
Xiaoming Zhang, Xingyu Zhou, Xiangtian Yu, Chuanfa Liu, Zhongjun Feng, Eagle SH Chu, Harry Cheuk-Hay Lau, Jiandong Zhang, Xiaoyan Bian, Tao Zeng, Xiang Zhang
Feasibility of achieving a tumor- and drug-free state through conversion therapy followed by curative hepatectomy for patients with initially unresectable hepatocellular carcinoma (GUIDANCE009)
Da-Long Yang, Yong-Rong Liang, Ze Su, Teng-Xian Zhou, Zhi-Cheng Li, Ming-Song Wu, Xue-Yao Wang, Hong-Bing Yao, Shao-Ping Liu, Jun-Liang Nong, Pei-Sheng Wu, Chuang Qin, Zhen Liu, Shu-Chang Chen, Jun-jie Ou, Teng-Meng Zhong, Yi-He Yan, Kang Chen, Zhi-Hao Huang, Lei-Po Lin, Yi-Li Ma, Liang Ma, Jian-Hong Zhong
Transarterial Chemoembolization Combined with Immunotherapy-Based Systemic Therapy for Hepatocellular Carcinoma: An International ISMIO Expert Consensus Framework
Bin-Yan Zhong, David Madoff, Arndt Vogel, Xuefeng Kan, Stephen L Chan, David J. Pinato, Yasuaki Arai, Julius Chapiro, Hai-Dong Zhu, Zhenwei Peng, Zhong-Zhi Jia, Peter Galle, Takeshi Okamoto, Kelvin Hong, Jon C Davidson, Aichi Chien, Chu Hui Zeng, Richard Finn, Masatoshi Kudo, Dong Xu, Gao-Jun Teng
Frequently asked questions
How long does it take to publish?
Accepted papers are published online in the unedited original manuscript version within a few days of acceptance. Authors should respond to proof queries within 48 hours. Articles are published electronically ahead of print shortly after author approval to publish.
Reformat to Liver Cancer using Livewrite PremiumIs a cover letter required?
A cover letter is required and should describe the gap in knowledge addressed by the manuscript, the implications and significance of the research, how the manuscript fits the journal scope, and the manuscript’s unique and important contributions. Submissions for a special issue or article collection should name the collection and identify who invited the submission where appropriate.
Reformat to Liver Cancer using Livewrite PremiumWhat are the publication costs?
Article Processing Charges (APCs) apply for Gold Open Access and Open Access options in hybrid journals; waivers and discounts are available for authors without means.
Reformat to Liver Cancer using Livewrite Premium